IQVIA Announces Comprehensive Multi-Tenant SaaS Safety Platform for Life Sciences Industry
January 08 2019 - 08:00AM
Business Wire
Significantly reduces the cost and complexity
of pharmacovigilance enabling organizations to focus on improving
patient safety
IQVIA™ (NYSE:IQV) today announced its development of a Software
as a Service (SaaS) safety platform that scales to address the drug
safety and surveillance challenges of life sciences organizations,
ranging from emerging biopharma to large pharmaceutical companies.
This SaaS solution is built to allow access from multiple users,
across multiple locations and will run on the Salesforce
architecture, the global leader in CRM and provider of SaaS
solutions.
“Drug safety organizations are burdened with outdated technology
that is inflexible and costly to maintain,” said Joe Rymsza, vice
president, Pharmacovigilance and Regulatory Technology Solutions at
IQVIA. “Our safety platform will leverage IQVIA’s industry
knowledge and advanced analytics to provide a step-change in
operations and will allow our customers to focus on the critical
task of improving patient safety.”
IQVIA’s multi-tenant safety platform will combine IQVIA’s deep
domain expertise, three thousand plus drug safety professionals,
and innovative process automation, machine learning and artificial
intelligence technologies, with IQVIA’s real world and regulatory
data to deliver actionable insights and streamline
pharmacovigilance operations.
A fundamental addition for IQVIA Technologies, the SaaS platform
will eliminate the need for costly upgrade projects and long
validation cycles. By leveraging automation to eliminate the costly
and repetitive manual processes associated with pharmacovigilance,
organizations will be able to evolve to zero-touch processing.
“IQVIA is strategically committed to providing our customers
with comprehensive pharmacovigilance technology and operational
services,” said Tal Rosenberg, senior vice president, Global
Technology Solutions at IQVIA. “This safety platform adds a
transformative dimension to our molecule-to-market technology
suite.”
Additional information about IQVIA’s safety platform is
available at www.iqvia.com.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced
analytics, technology solutions and contract research services to
the life sciences industry. Formed through the merger of IMS Health
and Quintiles, IQVIA applies human data science — leveraging the
analytic rigor and clarity of data science to the ever-expanding
scope of human science — to enable companies to reimagine and
develop new approaches to clinical development and
commercialization, speed innovation and accelerate improvements in
healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers
unique and actionable insights at the intersection of large-scale
analytics, transformative technology and extensive domain
expertise, as well as execution capabilities. With more than 55,000
employees, IQVIA conducts operations in more than 100
countries.
IQVIA is a global leader in protecting individual patient
privacy. The company uses a wide variety of privacy-enhancing
technologies and safeguards to protect individual privacy while
generating and analyzing the information that helps their customers
drive human health outcomes forward. IQVIA’s insights and execution
capabilities help biotech, medical device and pharmaceutical
companies, medical researchers, government agencies, payers and
other healthcare stakeholders tap into a deeper understanding of
diseases, human behaviors and scientific advances, in an effort to
advance their path toward cures. To learn more, visit
www.iqvia.com.
IQVIAFIN
Click here to subscribe to Mobile Alerts for IQVIA.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190108005472/en/
Tor ConstantinoIQVIA Media
Relationstor.constantino@iqvia.com+1.484.567.6732
Andrew MarkwickIQVIA Investor
Relationsandrew.markwick@iqvia.com+1.973.257.7144
IQVIA (NYSE:IQV)
Historical Stock Chart
From Feb 2024 to Mar 2024
IQVIA (NYSE:IQV)
Historical Stock Chart
From Mar 2023 to Mar 2024